扶正化瘀胶囊联合恩替卡韦片治疗乙型肝炎后肝硬化合并全身炎症反应综合征疗效观察  

Effect of Fuzheng Huayu Capsule combined with Entecavir Tablets on HBV-related hepatic cirrhosis complicated with systemic inflammatory syndrome

作　　者：董胜肖 刘惠敏[1] 刘文格[1] 靳海峰[1] DONG Shengxiao;LIU Huimin;LIU Wenge;JIN Haifeng(Bethune International Peace Hospital,Shijiazhuang 050082,Hebei,China)

机构地区：[1]解放军白求恩国际和平医院,河北石家庄050082

出　　处：《现代中西医结合杂志》2018年第33期3671-3674,共4页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的观察扶正化瘀胶囊联合恩替卡韦片治疗乙型肝炎后肝硬化合并全身炎症反应综合征的疗效。方法将306例乙型肝炎后肝硬化合并全身炎症反应综合征患者随机分为对照组和观察组,每组153例。对照组给予恩替卡韦片口服,观察组在对照组治疗基础上联合扶正化瘀胶囊口服,2组疗程均为24周。观察2组治疗前后透明质酸(HA)、Ⅲ型前胶原肽(PC-Ⅲ)、Ⅳ型胶原(Ⅳ-C)、层黏连蛋白(LN)、丙二醛(MDA)、晚期蛋白氧化产物(AOPPs)、谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆红素(TBil)、直接胆红素(DBil)及乙肝病毒DNA(HBV DNA)定量变化情况,统计2组治疗期间门静脉高压、肝性脑病、肝肾综合征和细菌感染的发生率和病死率。结果治疗后2组HA、PC-Ⅲ、Ⅳ-C、LN、ALT、AST、TBil水平和HBV DNA定量均明显降低(P均<0. 05),且观察组各指标降低的程度明显大于对照组(P均<0. 05)。治疗后2组MDA、AOPPs水平及对照组GSH-Px水平均明显降低(P均<0. 05),2组SOD水平均明显升高(P均<0. 05),且观察组各指标变化幅度较对照组更显著(P均<0. 05)。观察组门静脉高压、肝性脑病、肝肾综合征和细菌感染的发生率和病死率均明显低于对照组(P均<0. 05)。结论扶正化瘀胶囊联合恩替卡韦片可以有效治疗乙型肝炎后肝硬化合并全身炎症反应综合征,改善肝纤维化,其机制可能与减轻脂质过氧化损伤有关。Objective It is to observe the curative effect of Fuzheng Huayu Capsule combined with entecavir tablets in the treatment of HBV-related hepatic cirrhosis complicated with systemic inflammatory syndrome.Methods Three hundred and six patients with HBV-related hepatic cirrhosis complicated with systemic inflammatory syndrome were randomly divided into control group and observation group, 153 cases in each group. The control group was given entecavir tablets orally, and the observation group was treated with Fuzheng Huayu Capsule on the basis of the control group. The 2 groups were treated for 24 weeks. The changes of Hyaluronic acid （HA）, type Ⅲ procollagen peptide （PC-Ⅲ）, type Ⅳ collagen （Ⅳ-C）, laminin （LN）, malondialdehyde （MDA）, advanced protein oxidation products （AOPPs）, glutathione peroxidase （GSH-Px）, superoxide dismutase （SOD）, alanine aminotransferase （ALT）, aspartate aminotransferase （AST）, total bilirubin （TBil）, direct bilirubin （DBil） and hepatitis B virus DNA （HBV DNA） quantification were observed before and after treatment in both groups. The incidence of portal hypertension, hepatic encephalopathy, hepatorenal syndrome and bacterial infection and the mortality of the two groups were analyzed.Results After treatment, the levels of HA, PC-Ⅲ,Ⅳ-C, LN, ALT, AST, TBil and HBV DNA quantification in the two groups were significantly decreased （all P 〈0.05）, and the degree of reduction in the observation group was significantly higher than that in the control group （ P 〈0.05）. After treatment, the levels of MDA, AOPPs of the two groups and the level of GSH-Px of the control group were significantly decreased （all P 〈0.05）, the levels of SOD in the both groups were significantly increased （all P 〈0.05）, and the changes of the indicators in the observation group were significantly higher than those in the control group （all P 〈0.05）. The incidence of portal hypertension, hepatic encephalopathy, hepatorenal syndrome and

关 键 词：肝硬化 全身炎症反应综合征 肝纤维化 脂质过氧化 扶正化瘀胶囊 

分 类 号：R575.2[医药卫生—消化系统]